Oncopeptides AB (publ) (ONCO) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oncopeptides Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.887 -- 00:00:07.254 Hi everyone, and welcome to the presentation of Oncopeptides report for the first quarter 00:00:07.254 -- 00:00:12.778 of 2025. This is our standard disclaimer. 00:00:13.121 -- 00:00:18.348 I'm Sofia Hegis, CEO of Oncopeptides, and I'm joined as always by our CFO, Henrik 00:00:18.348 -- 00:00:21.713 Bergentoft, who will walk you through the financials. 00:00:21.713 -- 00:00:26.419 But let's begin by highlighting some key developments this quarter. 00:00:26.419 -- 00:00:29.528 The first quarter was a strong start to the year. 00:00:29.528 -- 00:00:34.915 Despite some headwinds in terms of weaker euro, which we sell in, compared to the Swedish 00:00:34.915 -- 00:00:40.243 krona, which we report in, and some seasonal effects that temporarily postpone treatments 00:00:40.243 -- 00:00:46.331 for certain patients, we delivered net sales of 13.3 million SEK. 00:00:46.331 -- 00:00:52.279 That means we almost tripled our sales compared to Q1 last year and see a 34% 00:00:52.279 -- 00:00:55.821 increase compared to Q4 of 2024. 00:00:55.853 -- 00:01:01.080 This growth was driven by continued traction in Germany and Spain while we are off 00:01:01.080 -- 00:01:06.227 to a good start in Italy. I will come back to more detailed updates on all of our 00:01:06.227 -- 00:01:08.209 key markets. 00:01:08.209 -- 00:01:13.075 Our cash position at the end of the quarter was 107 million SEK and Henrik will cover 00:01:13.075 -- 00:01:16.880 the financials in detail soon. Important 00:01:16.880 -- 00:01:23.246 to note is that we remain on track to reach cash flow positivity by the end of 2026. 00:01:23.765 -- 00:01:28.677 Our key milestone during the quarter was the positive reimbursement decision for PEPAXG 00:01:28.677 -- 00:01:33.788 in Italy that was ...